FREMONT, Calif., Sept. 3, 2019 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with ...

WALTHAM, Mass., Nov. 15, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

As a physician and researcher caring for people with chronic kidney disease, I see firsthand the challenges that patients undergoing dialysis face. Dialysis is life-sustaining, but it also brings ...

Tenapanor, a novel agent that has been submitted to the US Food and Drug Administration (FDA) for approval for the treatment of hyperphosphatemia in patients undergoing dialysis, moved a step closer ...

Given the suboptimal outcomes with existing therapies to manage chronic kidney disease patients on dialysis, there is a substantial unmet need that additional treatment options could potentially ...

LOS ALTOS, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. Once hyperphosphatemia occurs, we like to ...

Key companies active in the Hyperphosphatemia space include Phosphate Therapeutics, Bayer, Shire, Kyowa Kirin Co., Ltd., Shanghai Alebund Pharmaceuticals Limited ...